3-hydroxybutyric acid has been researched along with Multiple Sclerosis in 7 studies
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.
3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here, we report on the role of haptoglobin (Hp), whose expression depends on the synthesis of interleukin 6 (IL-6), related to the pathogenesis of multiple sclerosis (MS), as a possible marker of muscle improvement achieved after treatment with the polyphenol epigallocatechin gallate (EGCG) and an increase in the ketone body beta-hydroxybutyrate (BHB) in the blood." | 8.02 | Role of Haptoglobin as a Marker of Muscular Improvement in Patients with Multiple Sclerosis after Administration of Epigallocatechin Gallate and Increase of Beta-Hydroxybutyrate in the Blood: A Pilot Study. ( Benlloch, M; de la Rubia Ortí, JE; Escribá-Alepuz, J; Franco-Martinez, L; Platero, JL; Sancho-Castillo, S; Tvarijonaviciute, A, 2021) |
| "Here, we report on the role of haptoglobin (Hp), whose expression depends on the synthesis of interleukin 6 (IL-6), related to the pathogenesis of multiple sclerosis (MS), as a possible marker of muscle improvement achieved after treatment with the polyphenol epigallocatechin gallate (EGCG) and an increase in the ketone body beta-hydroxybutyrate (BHB) in the blood." | 4.02 | Role of Haptoglobin as a Marker of Muscular Improvement in Patients with Multiple Sclerosis after Administration of Epigallocatechin Gallate and Increase of Beta-Hydroxybutyrate in the Blood: A Pilot Study. ( Benlloch, M; de la Rubia Ortí, JE; Escribá-Alepuz, J; Franco-Martinez, L; Platero, JL; Sancho-Castillo, S; Tvarijonaviciute, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, JE | 1 |
| Titcomb, TJ | 1 |
| Bisht, B | 1 |
| Rubenstein, LM | 1 |
| Louison, R | 1 |
| Wahls, TL | 1 |
| Benlloch, M | 2 |
| Cuerda Ballester, M | 1 |
| Drehmer, E | 1 |
| Platero, JL | 2 |
| Carrera-Juliá, S | 1 |
| López-Rodríguez, MM | 1 |
| Ceron, JJ | 1 |
| Tvarijonaviciute, A | 2 |
| Navarro, MÁ | 1 |
| Moreno, ML | 1 |
| de la Rubia Ortí, JE | 2 |
| Franco-Martinez, L | 1 |
| Escribá-Alepuz, J | 1 |
| Sancho-Castillo, S | 1 |
| Kugelberg, E | 1 |
| Offermanns, S | 1 |
| Schwaninger, M | 1 |
| Netea, MG | 1 |
| Joosten, LA | 1 |
| Groß, CJ | 1 |
| Groß, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of an Online Course Designed to Support the Adoption of Healthier Diet and Self-Care Routines in Multiple Sclerosis Patients[NCT05057676] | 80 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | |||
| Efficacy of Diet on Quality of Life in Multiple Sclerosis[NCT05007483] | 156 participants (Anticipated) | Interventional | 2022-02-10 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for 3-hydroxybutyric acid and Multiple Sclerosis
| Article | Year |
|---|---|
Nutritional or pharmacological activation of HCA(2) ameliorates neuroinflammation.
Topics: 3-Hydroxybutyric Acid; Adenylyl Cyclases; Animals; Brain; Brain Ischemia; Diet, Ketogenic; Dimethyl | 2015 |
2 trials available for 3-hydroxybutyric acid and Multiple Sclerosis
4 other studies available for 3-hydroxybutyric acid and Multiple Sclerosis
| Article | Year |
|---|---|
Role of Haptoglobin as a Marker of Muscular Improvement in Patients with Multiple Sclerosis after Administration of Epigallocatechin Gallate and Increase of Beta-Hydroxybutyrate in the Blood: A Pilot Study.
Topics: 3-Hydroxybutyric Acid; Adult; Biomarkers; Catechin; Female; Haptoglobins; Humans; Interleukin-6; Mal | 2021 |
Inflammasome: starving inflammation.
Topics: 3-Hydroxybutyric Acid; Animals; Carrier Proteins; Caspase 1; Cryopyrin-Associated Periodic Syndromes | 2015 |
Inflammasome inhibition: putting out the fire.
Topics: 3-Hydroxybutyric Acid; Animals; Carrier Proteins; Caspase 1; Cryopyrin-Associated Periodic Syndromes | 2015 |
The Nlrp3 inflammasome admits defeat.
Topics: 3-Hydroxybutyric Acid; Animals; Carrier Proteins; Caspase 1; Cryopyrin-Associated Periodic Syndromes | 2015 |